Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer

Trastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies. Here, we integrated metabolomics, transcriptomics, and epigenomics data of trastuzumab-sensitive and primary-resistant HER2...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yijia Hua, Ningjun Duan, Chunxiao Sun, Fan Yang, Min Tian, Yanting Sun, Shuhan Zhao, Jue Gong, Qian Liu, Xiang Huang, Yan Liang, Ziyi Fu, Wei Li, Yongmei Yin
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2025-06-01
Series:	eLife
Subjects:	HER2-positive breast cancer trastuzumab primary resistance cysteine metabolism epigenetic modifications
Online Access:	https://elifesciences.org/articles/103953
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Olası Trastuzumab Kullanımına Bağlı Gelişen Pyojenik Granülom
by: Hilmi Cevdet Altınyazar, et al.
Published: (2013-01-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
by: Ana Lameirinhas, et al.
Published: (2025-03-01)

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
by: Yunus Emre Altıntaş, et al.
Published: (2024-12-01)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
by: Scott A Wu, et al.
Published: (2023-09-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review
by: Tao Wang, et al.
Published: (2025-03-01)

The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
by: Joseph Edward Haigh, et al.
Published: (2024-09-01)

HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab
by: Toàn Minh Ngô, et al.
Published: (2025-04-01)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
by: Ayaka Isogai, et al.
Published: (2023-06-01)

Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models
by: Zixin Yang, et al.
Published: (2025-05-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Intrathecal Trastuzumab as a Novel Simplified Therapeutic Strategy for Isolated Metastases in the Leptomeninges in HER2-Positive Breast Cancer: A Case Report and Review of Literature
by: Lokesh K. Nagendrappa, et al.

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category
by: Ana Catharina Joaquim, et al.
Published: (2025-08-01)

Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
by: Mariko Nishihara, et al.
Published: (2025-06-01)

Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report
by: Dalila Incognito, et al.
Published: (2025-06-01)

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
by: Wiebren Tjalma, et al.
Published: (2025-06-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Concordance of HER2-low scoring in breast carcinomas among pathologists
by: Snježana Tomić, et al.
Published: (2025-07-01)

Evaluation of the Effect of Radiotherapy Timing on Toxicity in HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine During the Adjuvant Period
by: İlknur Deliktaş Onur, et al.
Published: (2025-04-01)

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
by: Fangchao Zheng, et al.
Published: (2025-05-01)

Trastuzumab-emtansina versus otros regímenes anti-HER-2 en el cáncer de mama HER-2 positivo precoz o irresecable o metastásico: revisión sistemática y metaanálisis en red
by: Agustín Ciapponi, et al.
Published: (2024-03-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development
by: Narmin Nazeri, et al.
Published: (2025-07-01)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
by: Seema Gulia, et al.
Published: (2016-01-01)

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer
by: Xuchen Zhang, et al.
Published: (2025-07-01)

Development of Focal Nodular Hyperplasia Post Dual Anti-HER2 Blockade with Pertuzumab and Trastuzumab in a Patient with Breast Cancer: A Case Report and Literature Review
by: Udip Maheshwari, et al.

Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab
by: Jamila Mammadova, et al.
Published: (2025-05-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
by: Sila Oksuz, et al.
Published: (2025-04-01)

Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
by: Qi Cai, et al.
Published: (2025-12-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)